Vaxcyte, Inc.
NasdaqGS:PCVX Rapporto sulle azioni
Cap. di mercato: US$13.3b
Vaxcyte Performance dei guadagni passati
Il passato criteri di controllo 0/6 Gli utili di Vaxcyte sono diminuiti a un tasso annuo medio di -47.2%, mentre il settore Biotechs ha visto gli utili crescere a un tasso annuo di 19.3%.
Informazioni chiave
-47.2%
Tasso di crescita degli utili
28.9%
Tasso di crescita dell'EPS
Biotechs Crescita del settore 17.0% Tasso di crescita dei ricavi n/a Rendimento del capitale proprio -14.9% Margine netto n/a Ultimo aggiornamento sui guadagni 30 Sep 2024
Aggiornamenti sulle prestazioni recenti
Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 16
Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 17
Mostra tutti gli aggiornamenti
Co-Founder notifies of intention to sell stock Nov 04
Insufficient new directors Nov 01
President & CFO notifies of intention to sell stock Oct 20
Co-Founder notifies of intention to sell stock Oct 03
Executive VP & COO notifies of intention to sell stock Sep 18
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy Sep 06 Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion. Sep 06
Executive VP & COO notifies of intention to sell stock Sep 05 Vaxcyte, Inc. has filed a Follow-on Equity Offering. Sep 04
New major risk - Revenue and earnings growth Sep 03
Price target increased by 27% to US$131 Sep 03
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older Sep 03
We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate Aug 24
President & CFO notifies of intention to sell stock Aug 21
President & CFO notifies of intention to sell stock Jul 21
Vaxcyte Appoints John Furey to Board of Directors Jul 02
President & CFO notifies of intention to sell stock Jun 20
Independent Director notifies of intention to sell stock Jun 06
President & CFO notifies of intention to sell stock May 22
New major risk - Revenue and earnings growth May 10
Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry? May 10
President & CFO notifies of intention to sell stock Apr 22
Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024 Apr 16
President & CFO notifies of intention to sell stock Mar 20
New major risk - Revenue and earnings growth Mar 12
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants Mar 05
New major risk - Revenue and earnings growth Feb 23
President & CFO notifies of intention to sell stock Feb 22
Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 16 Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million. Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.
President & CFO notifies of intention to sell stock Jan 21
Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer Jan 17
Price target increased by 7.8% to US$71.14 Jan 06
Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise Jan 05
Co-Founder notifies of intention to sell stock Dec 29
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans Dec 27
Senior VP notifies of intention to sell stock Dec 10
Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases Dec 05
Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors Nov 29
President & CFO notifies of intention to sell stock Nov 24
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Nov 10
President & CFO notifies of intention to sell stock Oct 21
Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Oct 20
Co-Founder notifies of intention to sell stock Sep 27
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely Sep 12
Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation May 30
Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 17
President exercised options to buy US$1.1m worth of stock. Jan 08
Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults Jan 06
Executive VP & COO exercised options to buy US$5.1m worth of stock. Dec 30
We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth Dec 22
Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023 Dec 13
Independent Director exercised options and sold US$131k worth of stock Nov 16
High number of new directors Nov 16
Price target increased to US$60.50 Nov 12
Independent Director exercised options and sold US$147k worth of stock Oct 28
Price target increased to US$56.00 Oct 27
Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64 Oct 25
Co-Founder & VP of Research notifies of intention to sell stock Oct 15
Vaxcyte, Inc. Announces Executive Appointments Oct 12
Vaxcyte appoints new CBO, CMO Oct 11
Co-Founder notifies of intention to sell stock Sep 19
Co-Founder & VP of Research notifies of intention to sell stock Sep 10
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older Sep 07
Co-Founder notifies of intention to sell stock Aug 19
Co-Founder & VP of Research notifies of intention to sell stock Aug 08
Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs Aug 06
Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs Aug 05
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans Aug 05
Insider notifies of intention to sell stock Jul 31
Co-Founder notifies of intention to sell stock Jul 21
President & CFO notifies of intention to sell stock Jul 14
Vaxcyte, Inc. Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults Jul 13
Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate Jul 12
Executive VP & COO notifies of intention to sell stock Jul 08
Co-Founder notifies of intention to sell stock Jun 25
Co-Founder notifies of intention to sell stock May 20
Co-Founder & VP of Research notifies of intention to sell stock May 09
Insider notifies of intention to sell stock Apr 28
Co-Founder notifies of intention to sell stock Apr 27
High number of new directors Apr 27
Co-Founder notifies of intention to sell stock Apr 22
Vaxcyte, Inc., Annual General Meeting, Jun 01, 2022 Apr 21
Co-Founder & VP of Research notifies of intention to sell stock Apr 09
Vaxcyte, Inc. Announces Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in Adults Apr 06
President & CFO notifies of intention to sell stock Mar 24
Insider notifies of intention to sell stock Mar 15
Chief Operating Officer notifies of intention to sell stock Mar 01
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans Feb 25
Ripartizione dei ricavi e delle spese
Come Vaxcyte guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate NasdaqGS:PCVX Ricavi, spese e utili (USD Millions ) Data Ricavi Guadagni Spese G+A Spese di R&S 30 Sep 24 0 -508 82 447 30 Jun 24 0 -497 74 428 31 Mar 24 0 -437 67 369 31 Dec 23 0 -402 61 332 30 Sep 23 0 -300 55 280 30 Jun 23 0 -265 50 230 31 Mar 23 0 -245 45 196 31 Dec 22 0 -223 40 169 30 Sep 22 0 -174 35 141 30 Jun 22 0 -143 30 114 31 Mar 22 0 -118 27 93 31 Dec 21 0 -100 25 78 30 Sep 21 0 -92 23 70 30 Jun 21 0 -87 22 66 31 Mar 21 0 -83 19 67 31 Dec 20 0 -89 16 74 30 Sep 20 0 -83 14 72 30 Jun 20 0 -73 11 66 31 Mar 20 0 -64 11 57 31 Dec 19 0 -50 9 46 31 Dec 18 0 -29 5 30
Guadagni di qualità: PCVX al momento non è redditizia.
Margine di profitto in crescita: PCVX al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: PCVX non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 47.2% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di PCVX nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: PCVX non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 16.6% ).
Rendimento del capitale proprio
ROE elevato: PCVX ha un Return on Equity negativo ( -14.85% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
